Hepatitis B Before and After Hepatocellular Carcinoma

Harputluoglu M., Carr B.

JOURNAL OF GASTROINTESTINAL CANCER, cilt.52, sa.4, ss.1206-1210, 2021 (ESCI) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 52 Sayı: 4
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1007/s12029-021-00745-4
  • Dergi Adı: JOURNAL OF GASTROINTESTINAL CANCER
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1206-1210
  • Anahtar Kelimeler: Hepatitis B, Hepatocellular carcinoma, Prevention, TENOFOVIR DISOPROXIL FUMARATE, ANTIVIRAL THERAPY, CURATIVE TREATMENT, RISK, ENTECAVIR, PREVENTION, EFFICACY, TRANSMISSION, LAMIVUDINE, OUTCOMES
  • İnönü Üniversitesi Adresli: Evet

Özet

Hepatitis B virus (HBV) is the one of most common causes of the hepatocellular carcinoma (HCC), especially in eastern world. The aim of this review is to try to understand the relationship between HBV and HCC and to reveal the role of prevention and treatment of HBV infection in reducing the incidence of HCC. Strategies to prevent HCC due to HBV can be classified into three categories. These are primary, secondary, and tertiary preventions. Hepatitis B vaccine is now in the most vital position in preventing HBV-associated HCC. In patients with chronic hepatitis B infection, suppressing viral load with potent antivirals such as tenofovir disoproxil fumarate (TDF) and entecavir (ETV) prevents the development of HCC and improves prognosis by reducing recurrence after HCC treatments. There is currently no clear consensus on which of these drugs should be preferred. Although data on tenofovir alafenamide (TAF) are scarce, available data with TDF suggest that TAF therapy will also be a strong actor for HCC.